Regarding resistance to trastuzumab, in metastatic settings Lee and coworkers [25] reported in a larger cohort of HER2-positive primary BC that co-overexpression of the epidermal growth factor receptor (EGFR 1) may also be indicative for a poor prognosis and is associated with hormone receptor negativity. This evidence concerns the gene EGFR and breast cancer.